All of the other CBD Oil stocks have been trading down all month long on greater volume than usual, so CANB has actually been outperforming the sector by a pretty clear margin
The biggest difference between CANB and EDXC/CVSI/ELLXF/CWBHF is that CANB uses CBD Isolate as the foundation of their CBD Oil products and terpenes to create the entourage effect, whereas the other 4 stocks utilize Full Spectrum Extract as the foundation for their CBD Oil products, which also contains THC and CBG/CBN/CBC, etc.
Since all signs point to the FDA looking to only approve CBD Isolate and terpenes for national sales and enforcement discretion, the market is acting in a very rational fashion, as the risk in CANB is far lower and the reward is significantly higher than in any of the other CBD Oil stocks
The risk is much higher in the other CBD Oil stocks because they are using a formulation of their products which is very unlikely to receive FDA approval for national sales — CBD + THC + CBG/CBN/CBC, etc.
The reward is much higher in CANB because there is only 1 stock (not 4 stocks) in America using what’s expected to be the FDA’s choice of formulation for national sales — CBD Isolate + terpenes
The market has spoken
That’s the most rational explanation for CANB’s outperformance of the CBD Oil sector in September
News 
Market Data 
Discover 
AI
